Barry R Keith
Overview
Explore the profile of Barry R Keith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stevens K, Alligood K, Alberti J, Caferro T, Chamberlain S, Dickerson S, et al.
Bioorg Med Chem Lett
. 2008 Nov;
19(1):21-6.
PMID: 19028424
A novel class of pyrrolidinyl-acetyleneic thieno[3,2-d]pyrimidines has been identified which potently inhibit the EGFR and ErbB-2 receptor tyrosine kinases. Synthetic modifications of the pyrrolidine carbamate moiety result in a range...
2.
Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M, et al.
Cancer Res
. 2006 Feb;
66(3):1630-9.
PMID: 16452222
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential of lapatinib by testing its effect on...
3.
Gaul M, Guo Y, Affleck K, Cockerill G, Gilmer T, Griffin R, et al.
Bioorg Med Chem Lett
. 2003 Mar;
13(4):637-40.
PMID: 12639547
We have identified a novel class of 6-thiazolylquinazolines as potent and selective inhibitors of both ErbB-2 and EGFR tyrosine kinase activity, with IC(50) values in the nanomolar range. These compounds...
4.
Xia W, Mullin R, Keith B, Liu L, Ma H, Rusnak D, et al.
Oncogene
. 2002 Sep;
21(41):6255-63.
PMID: 12214266
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small molecule, GW572016, potently...